Get the Stockscreener App
1.18
4.42%
0.05
After Hours:
1.19
0.01
+0.85%
Entera Bio Ltd stock is traded at $1.18, with a volume of 67,603.
It is up +4.42% in the last 24 hours and down -7.09% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$1.13
Open:
$1.1597
24h Volume:
67,603
Relative Volume:
0.38
Market Cap:
$64.25M
Revenue:
$42,000
Net Income/Loss:
$-11.44M
P/E Ratio:
-4.7352
EPS:
-0.2492
Net Cash Flow:
$-7.93M
1W Performance:
+0.85%
1M Performance:
-7.09%
6M Performance:
-50.42%
1Y Performance:
-34.81%
1-Day Range:
$1.12
$1.20
1-Week Range:
$1.09
$1.25
52-Week Range:
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.18 | 61.53M | 42,000 | -11.44M | -7.93M | -0.2492 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - marketscreener.com
Entera Bio to Host Key Opinion Leader Webinar Highlighting - GlobeNewswire
Bear Alert: Should I invest in Entera Bio Ltd before earnings2026 Highlights & AI Powered Market Entry Strategies - baoquankhu1.vn
Entera Bio raises $10M in private placement led by BVF Partners - Investing.com Australia
Greenberg Traurig Represents Entera Bio in $10M Private Placement - National Today
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners - Finansavisen
Market Leaders: Is Entera Bio Ltd stock risky to hold now2026 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Entera Bio Ltd. Announces Private Placement and Securities Purchase Agreement for Phase 3 Osteoporosis Study Funding - Minichart
ENTX Technical Analysis & Stock Price Forecast - Intellectia AI
Entera Bio Announces $10 Million Private Placement Financing - TipRanks
Entera Bio Raises $10 Million in Private Placement With BVF Partners, Adds Registration Rights - TradingView — Track All Markets
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
Fresh $10M gives Entera Bio runway for Phase 3 osteoporosis study - Stock Titan
Entera Bio Ltd. announced that it expects to receive $10 million in funding - marketscreener.com
Net current asset value per share of Entera Bio Ltd. – LS:A2JQXP - TradingView
Stock market today: S&P 500, Dow futures gain as Trump calls Iran's new leaders 'very reasonable'—Palantir, Rezolve AI, Entera Bio in focus - MSN
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable' - Benzinga
Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In FocusState Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Entera Bio Ltd. Advances First-in-Class Oral Peptide Therapies for Osteoporosis, Hypoparathyroidism, and Metabolic Diseases – 2026 Annual Report Highlights - Minichart
Entera Bio Reports $18.7 Million Net Loss for 2025 and $1.2 Million in Revenue - geneonline.com
Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline - TipRanks
Entera Bio (NASDAQ:ENTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
ENTX: FDA-aligned EB613 Phase 3, pipeline advanced, net loss $11.4M, cash supports into Q3 2026 - TradingView
Entera 10-K: Revenue $0.042M, Loss Per Share $0.25 - TradingView
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Entera Bio (NASDAQ: ENTX) outlines oral osteoporosis and metabolic pipeline - Stock Titan
Entera Bio Ltd. Advances Oral Peptide Pipeline with Key FDA Submissions and Clinical Program Updates for Osteoporosis and Other Conditions - Quiver Quantitative
Entera Bio (NASDAQ: ENTX) 2025 loss widens as oral peptide pipeline advances - Stock Titan
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - Bitget
Entera Bio Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
S P Trends: Should I invest in Entera Bio Ltd before earnings2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market - The Globe and Mail
Entera May Be the 1st Winner of FDA's New Framework Redefining the Multi Billion Dollar Osteoporosis Market - Benzinga
If You Invested $1,000 in Entera Bio Ltd (ENTX) - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
What pushed Entera Bio (ENTX) to rally nearly 16% after hours - MSN
Entera Bio (ENTX) Expected to Announce Earnings on Friday - marketbeat.com
Analyst Upgrade: Is Entera Bio Ltd stock risky to hold now2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trend Review: Should I invest in Entera Bio Ltd before earnings2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Energy Moves: Can Entera Bio Ltd weather a recession2026 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline f - GuruFocus
Performance Recap: Is Entera Bio Ltd stock risky to hold now2026 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy - TipRanks
Entera Bio (NASDAQ:ENTX) Director Geno Germano Purchases 20,000 Shares - MarketBeat
Insider Buying: Geno Germano Acquires Additional Shares of Enter - GuruFocus
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):